CytoDyn Inc.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

Company to complete and submit responses to FDA clinical hold

CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues

Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board

CytoDyn Announces Appointment of Additional Directors with Industry Experience

Today, I'll discuss why new leadership brings new opportunities. I'll explain the concept of Net Present Value (NPV) and why it's utilized as a 'strategic assessment tool' to identify high value growth opportunities.

CytoDyn: Repositioning And Refocusing With New Leadership

VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Cyrus Arman, President, Antonio Migliarese, Chief Financial Officer, and Scott Kelly, Chief Medical Officer and Head of Business Development, will host an investment community webcast to provide a quarterly Company update on Wednesday, September 28, 2022.

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

TAMS for Non-Alcoholic Steatohepatitis NASH after topline PH2a results and what it could mean to Cytodyn long term investors. Wall Street modeling of non-revenue generating biotechs.

CytoDyn: It Only Takes One Hit

New York, New York--(Newsfile Corp. - August 12, 2022) - Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. ("CytoDyn" or the "Company") (OTCQB: CYDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether CytoDyn and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY) on behalf of CytoDyn stockholders. Our investigation concerns whether CytoDyn has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 6, 2022, CytoDyn disclosed in a filing with the U.S. Securitie

CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm

VANCOUVER, Washington, July 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Cyrus Arman as President effective July 9, 2022. Dr. Arman will be responsible for determining and leading the Company's operating strategy for the future. It is anticipated that he will advance to Chief Executive Officer and be appointed to the Board of Directors within six months. Antonio Migliarese, who had been serving as interim President since late January, in addition to CFO, will resume his previous role as CFO.

CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President

$5 Million Grant Awarded to OHSU for Preclinical Research of One-time Injection of Gene Therapy Based on Leronlimab for Functional Cure of HIV

CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab

CytoDyn seems to be dead in the waters. In my view, it is tough to assess leronlimab scientifically because the data they have generated is suspect.

CytoDyn: Nearly Impossible To Revive This Company

VANCOUVER, Washington, May 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has reached a non-cash settlement with its former Chief Medical Officer, Dr. Richard Pestell, concerning an ongoing legal dispute related to his former employment with the Company.

CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer

VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the addition of Dr. Paul Edison, Dr. Kabir Mody, and Dr. Otto Yang to the Company's Scientific Board of Advisors. In addition, Dr. Jay Lalezari has agreed to serve as an outside Scientific Advisor to the Company.

CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor

CytoDyn Inc, a late-stage biotechnology company developing its flagship drug leronlimab for multiple indications, has revealed the publication of a peer-reviewed research paper on the suppression of human and simian immunodeficiency virus replication with the help of leronlimab. The research paper titled “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species” was published in the open-access PLOS Pathogens journal.

CytoDyn touts publication of paper on suppression of human and simian immunodeficiency virus replication with leronlimab

VANCOUVER, Washington, April 12, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the publication of a peer-reviewed research paper entitled “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species” in the open-access journal PLOS Pathogens.

CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”

Live webcast to be held March 31 discussing announcement

CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program

CytoDyn made changes to the CEO position and the company's board of directors. The company appears to have secured finances to keep the lights on for the time being.

CytoDyn: Holding Onto The Ruins From An End Of An Era

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) --  CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations, will host an investment community webcast to provide an update on developments at the Company on Thursday, March 31, 2022.

CytoDyn to Hold Webcast to Provide Company Update

Shares of CytoDyn Inc. CYDY, -4.11% fell 4.9% in trading on Tuesday, the same day that the Food and Drug Administration issued a warning letter to the company over a video that features the former CEO falsely claiming that the company's experimental drug, leronlimab, clinically benefits COVID-19 patients. CytoDyn announced Jan. 24 that the board terminated Nader Pourhassan, the former president and CEO cited in the letter.

CytoDyn's stock falls 4% after getting warning letter from FDA about experimental COVID-19 treatment

Nader Pourhassan has been ousted as CEO and president by the board of directors of embattled Vancouver, Wash.

CytoDyn CEO ousted after year of lawsuits, FDA rebuke, and ongoing investigations

CytoDyn Inc, the biotech focused on the development and commercialization of leronlimab, has reported that it is on the hunt for a new CEO as it unveiled a leadership transition plan. With effect from January 24 this year, the company said it has terminated the employment of Dr Nader Z.

CytoDyn on the hunt for a new CEO as it unveils changes in leadership team

VANCOUVER, Wash.--(BUSINESS WIRE)--Today the Board of Directors (“the Board”) of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a leadership transition plan. Effective immediately, Antonio Migliarese, currently CytoDyn's Chief Financial Officer, has been appointed interim President. The Board of Directors terminated the employment of Nader Z. Pourhassan,

CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab

Yamana Gold

Genius Brands

Can penny stocks continue to make headway in 2022? The post Most Popular Penny Stocks to Buy Right Now?

Most Popular Penny Stocks to Buy Right Now? 3 For Your List

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has canceled its webcast scheduled for today, Thursday, January 13, 2022 and will provide an update at a future date. About Leronlimab The U.S. Food and Drug Administration (FDA) granted CytoDyn Fast Track designation to explore two potential indications using

CytoDyn Cancels Webcast and Live Q/A Scheduled for Today

VANCOUVER, Washington, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, Nitya Ray, Ph.D., Chief Operating Officer and Chief Technology Officer and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations of CytoDyn will host an investment community webcast to discuss and provide updates with regard to NASH data results (350 and 700 mg), Cancer, COVID-19, HIV BLA, and finances of the Company on Thursday, January 13, 2022.

CytoDyn to Hold Webcast and Live Q/A on January 13

CytoDyn Inc said a research paper indicated that its flagship drog leronlimab shows activity against 4-Class drug-resistant HIV-1 from heavily treatment-experienced (HTE) subjects. The Vancouver, British Columbia-based company noted that the research paper entitled “Leronlimab (PRO 140) activity against 4-class drug-resistant HIV-1 from Heavily Treatment Experienced Subjects” has been accepted, peer-reviewed and is available as a journal pre-proof on ScienceDirect.

News for CytoDyn Inc. Stock (CYDY)